Skip to main content

Autoinflammatory

ACR Best
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports: DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid…
RT @synovialjoints: Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions

Dr. Antoni Chan synovialjoints

6 months 2 weeks ago
Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease

Dr. Bella Mehta ( @bella_mehta) shares abstrac

Dr. John Cush RheumNow

6 months 2 weeks ago
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21.https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS
EULAR19.abstract.jpg (keep)
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…
RT @ericdeinmd: #ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA
⭐️⬆️IFN in models of HLH/MAS, neutralization may

Eric Dein ericdeinmd

6 months 2 weeks ago
#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA ⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful ⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC ⭐️Ok to continue IL1i ▶️13/14 pts remission ▶️ SAEs: 1 CMV reactivationhttps://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC
RT @bella_mehta: Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers

Bella Mehta bella_mehta

6 months 2 weeks ago
Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062
RT @Yuz6Yusof: #ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated M

Md Yuzaiful Md Yusof Yuz6Yusof

6 months 2 weeks ago
#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
×